RemeGen (SEHK:9995) Is Down 7.8% After US$650m AbbVie PD-1/VEGF Licensing Deal News - Has The Bull Case Changed?

Simply Wall St.01-26

Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606028261?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-26 02:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606028261","market":"nz","top_or_hot":-1,"title":"RemeGen (SEHK:9995) Is Down 7.8% After US$650m AbbVie PD-1/VEGF Licensing Deal News - Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-78-after-us650m-abbvie-pd-1vegf-lic\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen (SEHK:9995) Is Down 7.8% After US$650m AbbVie PD-1/VEGF Licensing Deal News - Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen (SEHK:9995) Is Down 7.8% After US$650m AbbVie PD-1/VEGF Licensing Deal News - Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 02:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-78-after-us650m-abbvie-pd-1vegf-lic><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-78-after-us650m-abbvie-pd-1vegf-lic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-78-after-us650m-abbvie-pd-1vegf-lic","article_id":"2606028261","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-78-after-us650m-abbvie-pd-1vegf-lic","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606028261","pubTimestamp":1769365122,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China in exchange for an upfront US$650 million payment plus very large potential milestone payments and tiered double-digit royalties.\nThe deal not only validates RemeGen’s oncology platform but also links RC148 to AbbVie’s antibody-drug conjugate pipeline, broadening future combination therapy...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4139":"生物科技","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","ABBV":"艾伯维公司","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK4559":"巴菲特持仓","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","PD":"PagerDuty, Inc.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","BK1161":"生物科技","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","09995":"荣昌生物"},"translate_title":"艾伯维6.5亿美元PD-1/VEGF许可交易消息传出后，RemeGen(SEHK：9995)下跌7.8%——牛市发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":0.9,"PD":1.5,"ABBV":1.5},"content_text":"Earlier in January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody for advanced solid tumors, giving AbbVie rights outside Greater China in exchange for an upfront US$650 million payment plus very large potential milestone payments and tiered double-digit royalties. The deal not only validates RemeGen’s oncology platform but also links RC148 to AbbVie’s antibody-drug conjugate pipeline, broadening future combination therapy possibilities. We’ll now examine how this substantial AbbVie licensing agreement, including the US$650 million upfront payment, reshapes RemeGen’s investment narrative. AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is RemeGen's Investment Narrative?For RemeGen, being a shareholder really comes down to believing that its oncology pipeline can justify a premium valuation despite ongoing losses of roughly CNY 947.63m and a price-to-sales multiple well above peers. The AbbVie deal is a clear swing factor here: the US$650m upfront payment materially strengthens the balance sheet and may ease near term funding pressure that previously loomed as a key risk, especially after recent equity issuance. It also adds a new short term catalyst around RC148 development and potential milestones that was not in the story before January 2026. That said, execution risk shifts higher too, with RemeGen now more exposed to clinical, regulatory and partnership progress on a single high profile asset, while still needing to manage dilution and buybacks carefully. However, one key clinical and partnership risk could change the story faster than many expect.\n\nDespite retreating, RemeGen's shares might still be trading 28% above their fair value. Discover the potential downside here.Exploring Other PerspectivesSEHK:9995 1-Year Stock Price Chart The single US$125.35 fair value estimate from the Simply Wall St Community points to one concentrated opinion rather than a spread of views. You are weighing that against a business still loss making, reliant on external capital and now significantly tied to RC148 and AbbVie for future progress, which can cut both ways depending on how trials evolve.Explore another fair value estimate on RemeGen - why the stock might be worth just HK$125.35!Build Your Own RemeGen NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your RemeGen research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free RemeGen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate RemeGen's overall financial health at a glance.Ready For A Different Approach?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606028261","isCrawlerRequest":true}